Financial Performance - The group recorded revenue of approximately HKD 914,280,000 for the six months ended June 30, 2024, a slight decrease of 0.2% compared to HKD 916,833,000 for the same period in 2023[1]. - The net loss for the group was approximately HKD 28,542,000, compared to a net profit of HKD 38,683,000 in the previous year, representing a significant decline[2]. - The group's gross profit increased to HKD 249,553,000, up 2.3% from HKD 242,462,000 in the prior year[2]. - The company reported a pre-tax loss of HKD 9,917,000 for the six months ended June 30, 2024, compared to a profit of HKD 58,100,000 in the same period of 2023[16][17]. - The net loss attributable to shareholders for the six months ended June 30, 2024, was HKD 47,676,000, compared to a profit of HKD 21,061,000 in the prior year[25]. - The company reported an unaudited loss of approximately HKD 28,542,000 for the six months ended June 30, 2024, compared to a profit of approximately HKD 38,683,000 for the same period in 2023[31]. Revenue Breakdown - Revenue from Hong Kong medical services reached HKD 394,462,000, up from HKD 389,333,000, indicating an increase of 1.5% year-over-year[12]. - Revenue from dental services increased to HKD 33,558,000, compared to HKD 29,757,000, representing a growth of 12.0%[12]. - Revenue from Hong Kong medical network management business was HKD 250,043,000, up from HKD 238,105,000, showing a growth of 5.0%[12]. - Revenue from hospital management and medical services in mainland China was HKD 264,377,000, down from HKD 283,378,000, reflecting a decrease of 6.7%[12]. - Total operating income from external customers in Hong Kong was HKD 649,903,000, compared to HKD 633,455,000 in the previous year[18]. Financial Position - The current ratio improved to 3.78 as of June 30, 2024, compared to 3.25 as of December 31, 2023, indicating better short-term financial health[1]. - The total assets less current liabilities amounted to HKD 3,786,395,000, down from HKD 3,903,194,000 at the end of 2023[5]. - The group's net asset value was approximately HKD 3,524,725,000 as of June 30, 2024, compared to HKD 3,618,746,000 at the end of 2023[1]. - The total liabilities to equity ratio remained low at 2.68% as of June 30, 2024, compared to 2.70% at the end of 2023[1]. - The group's current assets net value was approximately HKD 1,360,735,000, up from HKD 1,344,516,000 as of December 31, 2023, with a current ratio of 3.78 compared to 3.25 previously[56]. - The total equity attributable to the company's owners was approximately HKD 3,137,907,000 as of June 30, 2024, down from HKD 3,242,129,000 as of December 31, 2023[58]. Dividends and Share Performance - The group did not recommend an interim dividend for the six months ended June 30, 2024, consistent with the previous year[1]. - The company reported a basic and diluted loss per share of HKD 0.70 for the period, compared to earnings of HKD 0.31 per share in the previous year[3]. - The average number of shares used for calculating basic and diluted loss per share was 6,773,522,452 for the six months ended June 30, 2024[25]. Operational Highlights - The group operates a network of 422 medical service points, including 239 general practice points and 68 specialist points, with a total of 798 medical professionals as of June 30, 2024[37]. - The high-end integrated specialty brand, Zhongzhu Medical, has established a multi-specialty medical center in Hong Kong's core business district, offering 23 types of specialty medical services[40]. - The internet hospital at Nanshi Hospital has served over 850,000 patients since its launch in March 2022, currently offering services across 44 departments with around 400 doctors available online[42]. - The newly opened Nanyang Sports Rehabilitation Center integrates multiple disciplines and offers personalized health management plans, following the national strategy of integrating sports and medicine[43]. Challenges and Market Conditions - The overall economic environment remains challenging, with consumer spending growth in Hong Kong still weak, impacting the healthcare sector[38]. - Fair value losses on investment properties significantly increased to approximately HKD 26,870,000 for the six months ended June 30, 2024, from approximately HKD 2,896,000 in 2023, primarily due to a contraction in the Hong Kong property market[31]. - The company incurred finance costs of HKD 11,969,000 for the six months ended June 30, 2024, compared to HKD 10,915,000 in the same period of 2023[20]. Corporate Governance - The company has not complied with the corporate governance code C.2.1, as the roles of Chairman and CEO are held by the same individual, Mr. Cai Jiazan, which the board believes ensures consistent leadership and operational efficiency[67]. - The company is currently evaluating its governance structure and will continue to review the composition of its board[69]. Future Plans and Strategies - TBMG aims to integrate healthcare resources across Hong Kong and mainland China to build a comprehensive healthcare service ecosystem in the Greater Bay Area[49]. - Vio plans to enhance cooperation with self-operated and joint venture medical centers to capture more market share and drive revenue growth in 2024[51]. - The group plans to continue supporting government initiatives for primary healthcare development and actively participate in public-private partnership health programs in 2024[49].
康健国际医疗(03886) - 2024 - 中期业绩